- The 2018 BMJ article, by Wagner et al, is online here.
- The authors conclude, "The strength of the evidence cited by the NCCN supporting [non FDA labeled] recommendations is weak. Our findings raise concern that the NCCN justifies the coverage of costly, toxic cancer drugs based on weak evidence."
- The authors note that 6 of 44 NCCN recommendations progressed to FDA-labeled approval during the writing of the publication.
- Opinion piece in BMJ by senior author Vinay Prasad is here.
- See a like minded summary here.
- Trade press at Medscape here
- Trade press at CNN here.
- The last time this topic received a major airing was in 2009.
- Annals of Internal Medicine review by Abernethy et al. here.
- 2012 Deck by Abernethy at NAS, here.
- Additional 2009 piece in JNCI by Twombly, here.
- 2009 in NYTimes, here.
- A 2016 article in JAMA Oncology looked at financial conflicts among NCCN reviewers, Mitchell et al., here.
- Medicare regulations for the admission or exclusion of cancer compendia
- At 42 CFR 414.930, here.
- Rulemaking, November 27, 2007 (72 FR 66303ff) here.
- Revisions, November 25, 2009 (74 FR 61901ff) here.
- Medicare webpage for anticancer compendia here (numerous links).
- 2006 MedCAC on anti-cancer regimen compendia here.
In 2014, Wang et al. used a similar approach to critique the level of evidence used by FDA authors for inclusion of pharmacogenetic labeling in drug labels; here.